Phosphorylation of Nav1.5 at Ser571: Mechanistic Insights into Age-Related Cardiac Dysfunction

Study Background and Research Question

Aging is the predominant non-modifiable risk factor for chronic heart failure and arrhythmias in the population over 65 years old. Despite extensive research into structural and functional contributors to aging-associated cardiac myopathy, the primary molecular drivers have remained unclear. Notably, delayed ventricular repolarization and diastolic dysfunction are frequently observed in elderly patients, but their direct mechanistic origins have been debated. The reference study (Pizzo et al., 2024) interrogates whether age-associated increases in the cardiac late sodium current (INa,L) — specifically driven by phosphorylation of the Nav1.5 sodium channel at Ser571 — serve as a causative factor in the manifestation of aging myopathy.

Key Innovation from the Reference Study

The central innovation of this research lies in directly linking post-translational modification of Nav1.5 at Ser571 to both electrical and mechanical deficits in the aging heart. By employing genetically engineered mouse models with phosphomimetic (gain-of-function, GoF) or phosphoablated (loss-of-function, LoF) variants of Nav1.5, the authors demonstrate that phosphorylation at this site is sufficient to modulate late sodium current magnitude and, consequently, the propensity for age-related cardiac dysfunction. This approach allows for precise dissection of the molecular cascade translating ion channel modification into clinically relevant cardiac phenotypes.

Methods and Experimental Design Insights

The authors combined aging wild-type C57Bl/6 mice with Nav1.5 Ser571-targeted mutants to systematically assess the effects of altered late sodium current on cardiac electrophysiology and mechanics. Key aspects of the experimental design include:

• Use of both male and female mice to account for sex-dependent effects.
• Longitudinal comparison of young (3–5 months), adult (~5 months), and old (18–30 months) cohorts.
• Electrocardiogram (ECG) measurements to track QT interval duration as a surrogate for ventricular repolarization.
• In vitro cardiac electrophysiology: patch-clamp recordings of late INa in ventricular myocytes from different age groups and genotypes.
• Assessment of left ventricular (LV) filling and diastolic function via echocardiography and calcium transient kinetics.
• Pharmacological inhibition of INa,L to test reversibility of observed age-related defects.

The use of phosphomimetic and phosphoablated Nav1.5 mutants is particularly powerful, as it isolates the specific contribution of Ser571 phosphorylation to late sodium current and downstream pathophysiology, distinguishing it from broader age-related changes.

Core Findings and Why They Matter

Several key findings emerge from this comprehensive study:

• Increased late sodium current with age: Aging wild-type myocytes exhibited a ~60% increase in late INa compared to young cells, accompanied by a ~50% prolongation of action potential duration at 90% repolarization (Pizzo et al., 2024).
• Phosphorylation at Ser571 as a driver: Adult GoF mutants (phosphomimetic Nav1.5) prematurely displayed prolonged QT intervals and impaired LV filling, recapitulating defects typically seen only in aged wild-type mice. In contrast, LoF mutants (phosphoablated Nav1.5) showed minimal age-related deterioration.
• Impaired diastolic function and myocyte relaxation: Delayed calcium transient decay and myocyte relengthening were observed in aged wild-type and GoF mutants, but largely spared in LoF mice, pinpointing late sodium current as a modulator of diastolic mechanics.
• Reversibility by late sodium current inhibition: Pharmacological blockade of INa,L in aged wild-type mice rapidly reversed prolonged QT intervals and impaired diastolic filling, strongly supporting a causal relationship.

Collectively, these results establish that phosphorylation of Nav1.5 at Ser571 is a nodal mechanism linking electrical (delayed repolarization) and mechanical (diastolic dysfunction) phenotypes in the aging heart. This bridges a gap between molecular ion channel remodeling and the clinical progression of age-related cardiac myopathy, positioning late sodium current inhibition as a focused therapeutic and research target.

Comparison with Existing Internal Articles

Several recent internal articles have explored related themes, providing complementary perspectives and practical insights for researchers:

• The article "Nav1.5 Ser571 Phosphorylation Drives Age-Related Cardiac Dysfunction" expands on the molecular basis of increased INa,L in aged myocardium, echoing the reference study’s mechanistic conclusions and highlighting the translational relevance of late sodium current inhibition for arrhythmia prevention research.
• "GS967: Cardiac Late Sodium Current Inhibitor in Aging Research" details workflow integration of selective INa,L inhibitors like GS967 for in vitro cardiac electrophysiology and arrhythmia models, underscoring the utility of such compounds in mechanistic and translational studies.
• Internal resources also emphasize the reproducibility and selectivity of GS967 in aging and disease models, aligning with the reference study's finding that late sodium current inhibition reverses age-dependent electrical and functional deficits.

The convergence of molecular, electrophysiological, and pharmacological evidence across these resources strengthens the rationale for late INa inhibition as a research and therapeutic strategy in aging-associated cardiac dysfunction.

Limitations and Transferability

While the study provides robust evidence in genetically engineered mouse models, several limitations should be noted:

• Mouse cardiac physiology, while informative, does not fully recapitulate human disease complexity, particularly regarding arrhythmia susceptibility and drug responses.
• The focus on Nav1.5 Ser571 phosphorylation does not exclude contributions from other post-translational modifications or parallel signaling pathways in aging hearts.
• Pharmacological reversal of defects was demonstrated acutely; the long-term impact and safety of sustained late sodium current inhibition in aged organisms require further study.
• Translation to clinical settings will necessitate careful consideration of species differences, comorbidities, and the interplay with other age-associated cardiac remodeling processes.

Nevertheless, the mechanistic clarity and reproducibility of findings in this model set a solid foundation for future translational work.

Protocol Parameters

• Animal models: Use C57Bl/6 mice, with both wild-type and Nav1.5 S571 phosphomimetic/phosphoablated mutants; age groups should include young (3 months), adult (5 months), and old (18–30 months) animals to capture progressive changes.
• In vitro cardiac electrophysiology: Isolate ventricular myocytes for patch-clamp studies of late sodium current (INa,L); use selective inhibitors at concentrations supported by literature or validated product data.
• Functional assessment: Employ echocardiography for LV filling and diastolic function; record ECG for QT interval duration as a surrogate of ventricular repolarization.
• Pharmacological inhibition: Acute application of selective INa,L inhibitors to test reversibility of age-associated electrical and mechanical phenotypes.

Research Support Resources

To support in vitro cardiac electrophysiology and arrhythmia prevention research, the selective cardiac late sodium current inhibitor GS967 (SKU B5850) is widely used for its potency, selectivity, and reproducibility in both ventricular myocyte sodium current inhibition and ischemia-induced arrhythmia studies. According to product information and supporting articles, GS967 enables precise dissection of late sodium current contributions in aging and disease models, complementing genetic and molecular approaches (see internal workflow guide). Investigators are advised to consult both published protocols and supplier guidance from APExBIO for optimal experimental design.